{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:34:47Z","timestamp":1767983687618,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ijpharm.2016.06.054","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T08:23:24Z","timestamp":1466670204000},"page":"304-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form"],"prefix":"10.1016","volume":"510","author":[{"given":"Yuko","family":"Iwase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El-Sayed","family":"Khafagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Takeda-Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2016.06.054_bib0005","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.febslet.2013.04.031","article-title":"Cell-penetrating peptides: 20 years later, where do we stand?","volume":"587","author":"Bechara","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0020","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/nn4057269","article-title":"Cell-penetrating peptides: design, synthesis, and applications","volume":"8","author":"Copolovici","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0025","doi-asserted-by":"crossref","first-page":"18188","DOI":"10.1074\/jbc.271.30.18188","article-title":"Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent","volume":"271","author":"Derossi","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0030","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1600-0854.2007.00572.x","article-title":"A comprehensive model for the cellular uptake of cationic cell-penetrating peptides","volume":"8","author":"Duchardt","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0035","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0378-5173(81)90058-2","article-title":"Absorption of drugs from the nasal mucosa of rat","volume":"7","author":"Hirai","year":"1981","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2008.08.001","article-title":"Usefulness of cell-penetrating peptides to improve intestinal insulin absorption","volume":"132","author":"Kamei","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2009.02.015","article-title":"Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide\/protein absorption using cell-penetrating peptides","volume":"136","author":"Kamei","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jps.23364","article-title":"Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps","volume":"102","author":"Kamei","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0060","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1002\/jps.23708","article-title":"Mechanistic study of the uptake\/permeation of cell-penetrating peptides across a caco-2 monolayer and their stimulatory effect on epithelial insulin transport","volume":"102","author":"Kamei","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.xphs.2015.11.010","article-title":"Applicability and limitations of cell-penetrating peptides in noncovalent mucosal drug or carrier delivery systems","volume":"105","author":"Kamei","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2008.09.076","article-title":"Effect of cell-penetrating peptides on the nasal absorption of insulin","volume":"133","author":"Khafagy el","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2009.07.022","article-title":"Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins","volume":"381","author":"Khafagy el","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2009.12.060","article-title":"The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides","volume":"388","author":"Khafagy el","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0085","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ejpb.2013.09.014","article-title":"One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats","volume":"85","author":"Khafagy el","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0090","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1208\/s12248-015-9804-y","article-title":"Region-dependent role of cell-penetrating peptides in insulin absorption across the rat small intestinal membrane","volume":"17","author":"Khafagy","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2014.06.046","article-title":"PEG\u2014a versatile conjugating ligand for drugs and drug delivery systems","volume":"192","author":"Kolate","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0100","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00223-002-0034-9","article-title":"Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats","volume":"73","author":"Lee","year":"2003","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0105","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0120","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1096\/fj.05-5523com","article-title":"Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells","volume":"20","author":"Tunnemann","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ijpharm.2016.06.054_bib0125","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","article-title":"A truncated HIV-1 tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus","volume":"272","author":"Vives","year":"1997","journal-title":"Biol. Chem."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316305415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517316305415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T02:27:51Z","timestamp":1536632871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517316305415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0378517316305415"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.054","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}